Lisa Whittington, PharmD

Panelists discuss how advancing early detection, education, and collaboration will shape the pharmacist’s expanding role in the future of tardive dyskinesia care.

Panelists discuss how pharmacists help patients overcome cost and access barriers to maintain adherence and continuity of TD treatment.

Panelists discuss how pharmacists’ collaboration with multidisciplinary teams ensures comprehensive, patient-centered care in tardive dyskinesia management.

An expert pharmacist discusses how proactive counseling and monitoring by pharmacists are essential for managing side effects and maintaining adherence to TD therapy.

Panelists discuss how choosing between immediate- and extended-release VMAT2 inhibitor formulations can improve adherence and optimize treatment outcomes for tardive dyskinesia.

Panelists discuss how individualized care using VMAT2 inhibitors alongside careful medication management provides an effective, evidence-based approach to treating tardive dyskinesia.

An expert pharmacist discusses how identifying high-risk patients and minimizing unnecessary dopamine-blocking therapy are key steps in reducing the incidence of tardive dyskinesia.

An expert pharmacist discusses how early recognition and accurate diagnosis of tardive dyskinesia are vital to improving outcomes and quality of life for affected patients.